Maraviroc
{{drugbox | IUPAC_name = 4,4-difluoro-N-{(1S)-3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)- 8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide | image = Maraviroc.svg | CAS_number = 376348-65-1 | ATC_prefix = J05 | ATC_suffix = AX09 | PubChem = 3002977 | DrugBank = | C=29|H=41|F=2|N=5|O=1 | molecular_weight = 513.666 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }} Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. As of early 2007, it was undergoing clinical trials using the Trofile assay to determine participants' tropism.
On April 24 2007 the U.S. Food and Drug Administration advisory panel reviewing maraviroc's New Drug Application unanimously recommended approval for the new drug.[1]
On August 6 2007, the FDA granted accelerated approval of this compound.[2]
On September 24, 2007, Pfizer Inc. announced that the European Commission approved Celsentri (generic name, maraviroc and as Selzentry in the United States). Industry experts did forecast annual Celsentri sales of $500 million by 2011.[3]
References
- ↑ http://365gay.com/Newscon07/04/042407hiv.htm
- ↑ "Pfizer wins U.S. approval for new HIV drug". Retrieved 2007-08-06. Text " Reuters " ignored (help)
- ↑ Reuters, Europe gives final approval to Pfizer HIV drug
External links
- BBC News story: Drug 'stops HIV's entry to cells'
- Maraviroc data at aidsmap
- Maraviroc early access program
- New HIV Drug Recommended for Approval
- maraviroc at the US National Library of Medicine Medical Subject Headings (MeSH)
 | This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |